Drug Profile
GS 4774
Alternative Names: GI 13020; GS-4774; Inactivated recombinant Saccharomyces cerevisiae expressing Hepatitis B virus X, surface and core antigens (GI-13020); Tarmogen T cell immunity stimulatorLatest Information Update: 27 Sep 2021
Price :
$50
*
At a glance
- Originator GlobeImmune
- Developer Gilead Sciences
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 15 Jun 2018 GS 4774 is still in phase II trials for Hepatitis B (GlobeImmune pipeline, June 2018)
- 30 May 2018 Gilead Sciences completes a phase II trial in Hepatitis B (Combination therapy) in USA, Canada, New Zealand, Romania, South Korea and Italy (SC) (NCT02174276)
- 19 Apr 2017 Updated efficacy and immunological data from a phase II trial in Hepatitis B presented at the International Liver Congress (ILC-2017)